News | November 12, 2021
J.B Chemicals & Pharmaceuticals PAT at Rs 98 cr. in Q2FY22
J. B. Chemicals & Pharmaceuticals Limited (JBCPL), announced its financial results for the second quarter ended 30th September, 2021
J. B. Chemicals & Pharmaceuticals Limited (JBCPL), announced its financial results for the second quarter ended 30th September, 2021
The company has operations in North America, Asia, and Europe,
_256_384.jpg)
In several trials like Celestial (double-blind phase III trial), Phase III Meteor trials, Cabozantinib has shown better PFS (Progression-Free Survival).
The software enables real-time communication between patients, caregivers, physicians, and pharmacists and each cartridge in the device has a unique, traceable serial number registered to the patient
The company reports revenue growth of 26% and PAT growth of 21% YoY
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
TSC causes epilepsy in up to 85 % of patients, and up to 60 % of those patients do not respond to standard anti-seizure medicines
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Deal signed with AOP Orphan for US commercial rights
The drug is indicated for mild and transient episodes of heart block
Subscribe To Our Newsletter & Stay Updated
